U.S. Markets closed
  • S&P 500

    4,354.19
    -3.54 (-0.08%)
     
  • Dow 30

    33,919.84
    -50.63 (-0.15%)
     
  • Nasdaq

    14,746.40
    +32.49 (+0.22%)
     
  • Russell 2000

    2,186.18
    +3.98 (+0.18%)
     
  • Crude Oil

    70.51
    +0.22 (+0.31%)
     
  • Gold

    1,775.00
    +11.20 (+0.63%)
     
  • Silver

    22.53
    +0.37 (+1.68%)
     
  • EUR/USD

    1.1729
    +0.0001 (+0.0117%)
     
  • 10-Yr Bond

    1.3240
    +0.0150 (+1.15%)
     
  • Vix

    24.36
    -1.35 (-5.25%)
     
  • GBP/USD

    1.3663
    +0.0004 (+0.0314%)
     
  • USD/JPY

    109.2170
    -0.2030 (-0.1855%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,016.33
    -47.52 (-4.47%)
     
  • FTSE 100

    6,980.98
    +77.07 (+1.12%)
     
  • Nikkei 225

    29,839.71
    -660.34 (-2.17%)
     

U.S. Supreme Court snubs Novartis appeal over arthritis drug Enbrel

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

By Andrew Chung

May 17 (Reuters) - The U.S. Supreme Court on Monday dashed Novartis AG's hopes of launching a generic version of Amgen Inc's multibillion-dollar rheumatoid arthritis Enbrel, declining to hear the company's challenge to two patents on the drug.

The justices turned away Novartis subsidiary Sandoz Inc's appeal of a lower court decision that upheld the validity of the patents. (Reporting by Andrew Chung in New York; Editing by Will Dunham)